Skip to main content

Table 3 Relationship between clinicopathological characteristics and CD8+, CD56+, CD57+, GNLY+, and GZMB+ TIL subsets

From: Characterization of tumor-infiltrating lymphocytes and their spatial distribution in triple-negative breast cancer

Clinicopathological characteristics

CD8+ TIL

CD56+ TIL

CD57+ TIL

GNLY+ TIL

GZMB+ TIL

No. of TILs

p value

No. of TILs

p value

No. of TILs

p value

No. of TILs

p value

No. of TILs

p value

Age (year)

 

0.990

 

0.027

 

0.306

 

0.052

 

0.473

 < 50

198.2 (113.7-332.3)

 

2.3 (0.1–6.9)

 

7.7 (1.4–15.7)

 

17.8 (6.1–36.5)

 

7.7 (1.0–31.0)

 

 ≥ 50

220.3 (80.3-377.3)

 

0.7 (0.0-4.3)

 

5.7 (0.7–13.7)

 

11.3 (2.0–30.0)

 

5.3 (1.3–22.3)

 

Histologic type

 

0.422

 

0.755

 

0.779

 

0.938

 

0.979

 IC-NST

200.0 (89.1-362.2)

 

1.7 (0.0–6.0)

 

6.7 (1.0-15.7)

 

13.4 (3.3–34.1)

 

7.5 (1.0-25.5)

 

 Othersa

255.3 (144.2-331.9)

 

1.7 (0.2–6.4)

 

5.0 (0.7–13.4)

 

10.7 (1.0-48.4)

 

7.3 (1.5–31.4)

 

T stage

 

0.044

 

0.066

 

0.098

 

0.005

 

0.024

 T1-2

217.3 (112.4-362.5)

 

2.0 (0.0–6.0)

 

6.7 (1.1–15.7)

 

14.7 (4.3–35.7)

 

7.7 (1.1–26.0)

 

 T3-4

70.0 (5.7-256.7)

 

0.0 (0.0-0.3)

 

0.7 (0.0-8.7)

 

1.3 (0.0–7.0)

 

0.3 (0.0-9.7)

 

N stage

 

0.540

 

0.343

 

0.374

 

0.083

 

0.125

 N0

221.7 (87.2-373.3)

 

2.0 (0.0–6.0)

 

6.9 (1.1–15.8)

 

13.9 (4.7–39.9)

 

8.5 (1.1–26.0)

 

 N1-3

188.3 (118.3-294.7)

 

1.0 (0.0–5.0)

 

5.7 (1.0-12.3)

 

12.0 (2.0-19.3)

 

2.3 (0.3–20.0)

 

AJCC stage

 

0.410

 

0.087

 

0.161

 

0.147

 

0.030

 I-II

219.8 (102.3-365.2)

 

2.0 (0.0–6.0)

 

6.9 (1.0-15.9)

 

14.2 (3.6–36.5)

 

8.2 (1.3–26.0)

 

 III

153.3 (115.7-294.7)

 

0.3 (0.0–4.0)

 

3.3 (0.5-8.0)

 

10.7 (2.0-16.7)

 

1.0 (0.0-7.3)

 

LVI

 

0.169

 

0.001

 

0.002

 

0.001

 

0.021

 Absent

232.3 (117.3–374.0)

 

2.7 (0.0-7.3)

 

8.3 (1.3–18.3)

 

20.3 (4.7–46.0)

 

9.7 (1.3–31.7)

 

 Present

170.3 (86.4-315.8)

 

0.6 (0.0-3.3)

 

5.0 (0.4–8.5)

 

11.0 (2.0-19.2)

 

2.3 (0.4–20.0)

 

Histologic grade

 

0.335

 

0.066

 

0.080

 

0.009

 

0.041

 II

144.7 (67.5-288.5)

 

0.0 (0.0-3.7)

 

1.3 (0.2–10.7)

 

1.3 (0.3–17.2)

 

1.3 (0.0-4.5)

 

 III

217.3 (109.3-362.2)

 

2.0 (0.0–6.0)

 

6.9 (1.2–15.8)

 

14.7 (4.7–36.7)

 

8.2 (1.0–26.0)

 

Nuclear pleomorphism

 

0.104

 

0.516

 

0.505

 

0.032

 

0.382

 2

127.3 (46.0-292.3)

 

0.0 (0.0-7.3)

 

7.3 (0.3–11.7)

 

0.7 (0.3–22.7)

 

1.7 (0.0-39.3)

 

 3

219.8 (110.6–357.0)

 

1.7 (0.0–6.0)

 

6.5 (1.1–15.6)

 

14.0 (4.7–35.7)

 

7.7 (1.0-24.7)

 

DCIS component

 

0.157

 

0.006

 

0.066

 

0.002

 

0.020

 Absent

254.7 (113.8-369.1)

 

3.0 (0.5–9.2)

 

8.7 (1.6–18.7)

 

24.5 (9.6–56.7)

 

14.5 (2.7–35.3)

 

 Present

179.3 (103.7-331.3)

 

1.0 (0.0–5.0)

 

6.0 (0.7–12.7)

 

11.3 (2.4–27.7)

 

3.7 (0.7–22.3)

 

Tumor border

 

0.229

 

0.038

 

0.011

 

< 0.001

 

0.002

 Pushing

234.0 (120.7–366.0)

 

2.0 (0.0-7.7)

 

8.0 (2.0–17.0)

 

21.3 (6.7–46.3)

 

14.3 (1.0–35.0)

 

 Infiltrative

185.5 (87.4-319.7)

 

1.4 (0.0–4.0)

 

3.7 (0.7–10.3)

 

6.9 (1.5–17.8)

 

2.2 (1.0-15.4)

 

Multicentricity

 

0.524

 

0.951

 

0.645

 

0.994

 

0.911

 Absent

217.3 (86.3–347.0)

 

1.9 (0.0–6.0)

 

6.7 (1.0-15.7)

 

13.0 (2.5–36.0)

 

7.3 (1.0-23.4)

 

 Present

190.3 (140.3-345.2)

 

1.0 (0.2–4.2)

 

6.3 (0.9–13.0)

 

14.3 (5.8–31.5)

 

8.7 (1.0-32.5)

 

Ki-67 index

 

0.028

 

0.011

 

0.111

 

0.003

 

0.015

 < 50%

154.6 (77.8–302.0)

 

0.9 (0.0-4.1)

 

5.9 (0.7–13.2)

 

11.0 (1.3–22.7)

 

2.7 (0.7–20.1)

 

 ≥ 50%

250.3 (122.9-377.8)

 

3.0 (0.3-7.0)

 

8.0 (2.0-16.5)

 

21.3 (6.5–42.7)

 

14.7 (1.3–36.7)

 

p53 overexpression

 

0.568

 

0.815

 

0.629

 

0.339

 

0.831

 Absent

192.3 (84.5-362.4)

 

1.7 (0.0–6.0)

 

6.7 (0.9–16.5)

 

11.7 (1.3–32.8)

 

8.7 (0.7–22.4)

 

 Present

221.7 (109.3-334.5)

 

1.7 (0.0-5.4)

 

6.5 (1.2–15.0)

 

14.5 (5.2–36.0)

 

6.8 (1.2–26.6)

 

Basal phenotype

 

0.385

 

0.515

 

0.397

 

0.844

 

0.552

 Absent

155.5 (86.3-292.3)

 

2.0 (0.0–7.0)

 

7.0 (0.3–13.0)

 

16.7 (0.7–34.3)

 

7.3 (0.5–22.7)

 

 Present

219.8 (107.6–357.0)

 

1.7 (0.0-5.3)

 

6.5 (1.1–15.6)

 

13.0 (4.3–35.3)

 

7.5 (1.0-27.7)

 
  1. Data are presented as median (inter-quartile range), and p values were calculated by Mann-Whitney U test
  2. aInclude metaplastic carcinoma and carcinoma with apocrine differentiation
  3. TIL, tumor-infiltrating lymphocyte; GNLY, granulysin; GZMB, granzyme B; IC-NST, invasive carcinoma of no special type; AJCC, American Joint Committee on Cancer; LVI, lymphovascular invasion; DCIS, ductal carcinoma in situ
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us